NRG-GY018 Trial Design and Outcomes
The NRG-GY018 (KEYNOTE-868) trial demonstrated that pembrolizumab 200 mg every 3 weeks combined with carboplatin-paclitaxel chemotherapy for 6 cycles, followed by pembrolizumab 400 mg every 6 weeks maintenance for up to 14 additional cycles (total ~24 months), significantly improved progression-free survival in both mismatch repair-deficient (dMMR) and mismatch repair-proficient (pMMR) advanced or recurrent endometrial cancer patients, establishing this as the new standard first-line treatment. 1, 2
Trial Design
This was a multicenter, randomized, double-blind, placebo-controlled phase 3 trial that enrolled 810 patients with advanced or recurrent endometrial carcinoma 1, 2. The study stratified patients into two separate cohorts:
- dMMR cohort: 222 patients (27%)
- pMMR cohort: 588 patients (73%)
Eligibility Criteria
Patients were eligible if they had:
- Measurable Stage III disease
- Measurable Stage IVA disease
- Stage IVB disease (with or without measurable disease)
- Recurrent endometrial cancer (with or without measurable disease)
Critical inclusion: Patients must have received no prior systemic therapy OR had received prior adjuvant chemotherapy with a chemotherapy-free interval of at least 12 months 1.
Key exclusions: Endometrial sarcoma (including carcinosarcoma), active autoimmune disease, or conditions requiring immunosuppression 1.
Dosing Regimen
The treatment protocol consisted of two phases:
Induction Phase (6 cycles)
- Pembrolizumab: 200 mg IV every 3 weeks
- Paclitaxel: 175 mg/m² IV every 3 weeks
- Carboplatin: AUC 5 mg/mL/min IV every 3 weeks
All medications administered on Day 1 of each 3-week cycle 1.
Important modification: Patients with measurable disease who achieved stable disease or partial response after cycle 6 could continue paclitaxel-carboplatin with pembrolizumab for up to 10 total chemotherapy cycles 1.
Maintenance Phase (up to 14 cycles)
- Pembrolizumab: 400 mg IV every 6 weeks as monotherapy
- Maximum total treatment duration: 20 cycles (~24 months) 1
Primary Outcomes: Progression-Free Survival
dMMR Cohort (Mismatch Repair-Deficient)
The results were dramatic: At 12 months, 74% of pembrolizumab-treated patients remained progression-free compared to only 38% with placebo-chemotherapy alone 2.
- Hazard ratio: 0.30 (95% CI 0.19-0.48; P<0.001)
- Risk reduction: 70% relative reduction in progression or death 2
- This represents one of the most substantial treatment effects seen in gynecologic oncology
pMMR Cohort (Mismatch Repair-Proficient)
The benefit was more modest but still clinically meaningful:
- Median PFS with pembrolizumab: 13.1 months
- Median PFS with placebo: 8.7 months
- Hazard ratio: 0.54 (95% CI 0.41-0.71; P<0.001) 2
Blinded Independent Central Review
Exploratory analysis using BICR confirmed the investigator-assessed findings 3:
- pMMR cohort HR: 0.64 (95% CI 0.49-0.85; P=0.0008)
- dMMR cohort HR: 0.45 (95% CI 0.27-0.73; P=0.0005)
Secondary Outcomes: Overall Survival
At the time of primary analysis, OS data were immature but showed favorable trends 3:
- pMMR cohort HR: 0.79 (95% CI 0.53-1.17; 1-sided P=0.1157)
- dMMR cohort HR: 0.55 (95% CI 0.25-1.19; 1-sided P=0.0617)
The OS benefit appears more pronounced in the dMMR population, though neither reached statistical significance at interim analysis 3.
Safety Profile
Adverse events were consistent with the known toxicity profiles of pembrolizumab and carboplatin-paclitaxel chemotherapy 2. The combination did not introduce unexpected safety signals, though immune-related adverse events must be monitored and managed appropriately.
Clinical Implementation
This trial directly led to FDA approval and guideline recommendations 4, 1:
- For dMMR tumors: Pembrolizumab plus carboplatin-paclitaxel followed by pembrolizumab maintenance is now the preferred first-line therapy (Level I, Grade A evidence) 4
- For pMMR tumors: This combination can be considered as first-line treatment (Level I, Grade B evidence) 4
Monitoring Schedule
Tumor assessment was performed:
- Every 9 weeks for the first 9 months
- Every 12 weeks thereafter 1
Key Clinical Pearls
The magnitude of benefit differs substantially by MMR status: The dMMR population derives exceptional benefit (70% risk reduction), while pMMR patients have more modest but still meaningful improvement. This underscores the critical importance of MMR testing before treatment initiation 4, 5.
Duration matters: The maintenance phase extends to approximately 24 months total, which is longer than some competing regimens and may impact cost-effectiveness 6.